|
|
- 2017
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB studyDOI: 10.1016/j.trci.2017.05.003 Keywords: Alzheimer's disease, Antibody, Amyloid, Pharmacokinetics, Pharmacodynamics, Ponezumab, PIB, Safety, Tolerability, Anti-drug antibodies Abstract: The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti-Aβ monoclonal antibody, were characterized in subjects with mild-to-moderate Alzheimer's disease treated for 1 year
|
